









Markets
/
Stocks
/
nasdaq-vrca
/

Verrica Pharmaceuticals Inc

VRCA

4.390USD

+0.350+8.66%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

40.63MMarket Cap

LossP/E TTM



Verrica Pharmaceuticals Inc

4.390

+0.350+8.66%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

64 / 175

Overall Ranking

202 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

15.000

Target Price

+271.29%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Growing

The company is in a growing phase, with the latest annual income totaling USD 7.57M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 212.73.

Overvalued

The company’s latest PE is -0.57, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 8.91M shares, increasing 26.14% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 216.83K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.95.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.43, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 12.70M, representing a year-over-year increase of 145.35%, while its net profit experienced a year-over-year increase of 101.19%.

Score

Industry at a Glance

Previous score

7.43

Change



Financials

6.77

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

2.73

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.67

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -0.52, which is 52.24% below the recent high of -0.80 and -779.14% above the recent low of -4.60.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 64/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.20, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Verrica Pharmaceuticals Inc is 15.00, with a high of 20.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

7.20

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

15.000

Target Price

+271.29%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Verrica Pharmaceuticals Inc

VRCA

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.50, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 5.71 and the support level at 3.17, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.50

Change

0.26

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.358

Neutral

RSI(14)

41.078

Neutral

STOCH(KDJ)(9,3,3)

20.852

Buy

ATR(14)

0.417

High Vlolatility

CCI(14)

-109.557

Sell

Williams %R

73.785

Sell

TRIX(12,20)

-0.692

Sell

StochRSI(14)

57.407

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

4.438

Sell

MA10

4.699

Sell

MA20

5.103

Sell

MA50

4.645

Sell

MA100

2.617

Buy

MA200

1.636

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 96.35%, representing a quarter-over-quarter increase of 26.78%. The largest institutional shareholder is The Vanguard, holding a total of 216.83K shares, representing 2.30% of shares outstanding, with 10.58% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Manning (Paul B.)

31.38M

+126.54%

Caligan Partners, LP

8.99M

+21.04%

Armistice Capital LLC

8.57M

-3.96%

BKB Growth Investments LLC

5.98M

The Vanguard Group, Inc.

Star Investors

2.36M

+25.61%

Stalfort (John A)

1.87M

+14.56%

Millennium Management LLC

395.65K

Rieger (Jayson)

889.88K

+50.91%

Sovran Advisors LLC

392.16K

-3.66%

Geode Capital Management, L.L.C.

1.02M

+113.40%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.05, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 1.74. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.